Rallybio

Rallybio is a clinical-stage biotechnology company dedicated to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases. Since its launch in January 2018, Rallybio has built a promising portfolio of product candidates currently in development to address rare diseases in areas such as hematology, immune-inflammatory disorders, maternal-fetal health, and metabolic disorders. The company is driven by a team of experienced biopharmaceutical industry leaders with extensive research, development, and rare disease expertise. Rallybio is headquartered in New Haven, Connecticut, with an additional facility at the University of Connecticut Technology Incubation Program in Farmington, Connecticut.The company’s lead product candidate, RLYB211, is being developed for the prevention of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT), a potentially life-threatening rare disease that can cause bleeding in fetuses and newborns.